Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.

Slides:



Advertisements
Similar presentations
Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
Differences in the availability of medicines used for chronic and acute conditions in developing countries Alexandra Cameron International Conference on.
MEDICINES SELECTION & FORMULARY MANAGEMENT
Presented to CSO workshops in Kabwe on 18 July 2014, Livingstone on 28 July 2014 and Lusaka on 27 August 2014.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Generating Information for Medicines Benefit Management: A Systems Framework Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health.
1208 Evidence on Access to and Use of Medicines to Treat Chronic Diseases from Household Surveys in Five Low and Middle Income Countries.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Medicines Transparency Alliance Presented by Deirdre Dimancesco Department of Essential Medicines and Health Products, WHO at the Technical Briefing Seminar.
Antibiotic Policy in Ghana; the way forward
Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:
Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.
Abstract 213 ICIUM: Antalya, Turkey. November 14-18, 2011.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.
Essential Medicines Programmes Sudan now Essential Medicines Programmes Sudan now.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
Medicines Transparency Alliance05/09/2015 Medicine Promotion Robert Louie P. So, MD Program Manager DOH - National Center for Pharmaceutical Access and.
MULTI-STAKEHOLDER COLLABORATION: CAN IT IMPROVE TRANSPARENCY, DISCLOSURE AND ACCESS TO MEDICINES? EXPERIENCES FROM 7 META PILOT COUNTRIES Wilbert Bannenberg.
UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT.
Wilbert Bannenberg, Technical Director MeTA International Secretariat IACC 14 Bangkok, 13 November 2010 MeTA multi-stakeholder process – a way to improve.
Wilbert Bannenberg SARPAM
Data Disclosure: An Ongoing Progress Towards Transparency Abeer Rabayah B.Sc Pharmacy -MBA /Marketing MeTA National Coordinator.
Medicines Transparency Alliance03/10/ MeTA Zambia Violet Kabwe MeTA Zambia Consultant.
Universal Health Coverage – Achieving Access and Responsible Use of Medicines 2015 AGM Of The Pharmaceutical Society of Ghana Thematic Speaker Emmanuel.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Medicines Transparency Alliance10/10/2015 Updates on Quality Presentations et al. John Allotey Manager, Business Developments LaGray Chemical Company Limited.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Medicines Transparency Alliance14/10/ Medicines promotion: innovative tools to promote rational use Carole Piriou Project officer Rational use of.
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
1 Towards a Medicines Transparency Alliance (MeTA) Richard Laing and Ali Cameron with slides prepared by Michael Borowitz, DfID WHO Technical Briefing.
Uganda Health Information Strategy Eddie Mukooyo, MD, MSc Assistant Commissioner Health Services Dublin, Ireland 13 th September 2010.
4 th - 18 November 2011 ICIUM 2011 Conference Antalya, Turkey 16/10/2015.
Samia Saad 1, Birgit Kerstens 2, Wilbert Bannenberg 1,2 1 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2 Health Research for Action (HERA),
Medicines Transparency Alliance18/10/ Towards Improving Availability of Essential Medicines in Jordan’s Public Health Sector Presenter Name Job Title.
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
Medicines Transparency Alliance27/10/ MeTA Ghana Augustina Koduah (Mrs) Country Coordinator.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Objective the aim of this project was directly addressing a major health problem for Jordan by producing a guideline as a pilot in which the strengths.
Medicines Transparency Alliance15/11/ MEDICINES AVAILABILITY - PHILIPPINES Alexander A. Padilla Undersecretary of Health Vice Chairman, MeTA Philippines.
Medicines systems: Convergence for access Dr Socorro Escalante WHO Country Office for Viet Nam 1.
Designing and Managing Medicines Benefits – Goals, Policy Options, Ethical Considerations Anita Katharina Wagner Department of Population Medicine Harvard.
1 Pharmaceutical System Strengthening: Is There a Need for a New Paradigm? Douglas Keene, PharmD, MHS ICIUM-3 Pre-Conference Session 14 November 2011.
Medicines Transparency Alliance Presented by Gilles Forte Department of Essential Medicines and Health Products, WHO On behalf of WHO and HAI Technical.
SURVEY OF HEALTH FINANCING SYSTEMS FOR ACCESS TO MEDICINES BY THE POOR IN RURAL AND URBAN PHILIPPINES A Research Study Funded by MeTA Philippines May 2010.
Stop the Stock-outs! Access to Essential Medicines for All Christa Cepuch BSc Phm Health Action International Africa RHS Coalition Meeting 27 May 2010,
Indicators for monitoring and assessing pharmaceutical situation in countries.
Medicines Transparency Alliance16/12/2015 Pricing: Observations Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O.
Medicines Transparency Alliance18/12/ Country overview MeTA Kyrgyzstan Mariam Djankorozova MeTA Country coordinator.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
Indicators for monitoring and assessing pharmaceutical situation in countries Dr. Edelisa D. Carandang Drug Action Program (DAP) Essential Drugs and Medicines.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
ADDRESSING PHARMACEUTICAL SUPPLY CHAIN NEEDS PRESENTATION TO HEALTH DONOR GROUP MEETING 8 July 2009.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team.
Wilbert Bannenberg SARPAM
Implementing the guideline
Managerial and Regulatory Strategies to Improve Drug Use
Toktobaeva B, Karymbaeva S Drug Information Centre Kyrgyzstan
Presentation transcript:

Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy

Medicines Transparency Alliance Evidence on Medicines Availability MeTA facility surveys – Supply side assessment – Average public sector generic availability 30%-55%* – Generics in public facilities < generics in private facilities – Generics for chronic conditions < generics for acute conditions MeTA household surveys – Add demand side perspective – Consumer perceptions seem consistent with facility data Public facilities < private facilities Chronic disease medicines < acute condition medicines – Lack of public sector availability seems to impact adherence Differently for poor, near-poor, less poor *Cameron et al, Lancet, /10/2015

Medicines Transparency Alliance Key Observations Appropriate, high-quality, affordable medicines must be available for health care to improve health Availability is complex, multi-factorial – International and national regulations – Manufacturing – Forecasting to match clinical need, guideline-based treatment, & drug lists – Procurement, distribution, warehousing logistics – Financing within systems, for patients – Incentives for manufacturer, purchasers, prescribers, dispensers – Education, training, awareness generation of all stakeholders (logistics, cost, appropriate prescribing, dispensing, use) Fragmented, decentralised health care systems challenge availability further 01/10/2015 Multi-pronged, multi-level, multi-stakeholder approaches essential to improving availability

Medicines Transparency Alliance Sample Interventions in MeTA Countries Regulation – Generic laws (Philippines) – Legislation for price reductions to increase availability for middle class (Philippines) – “New law on medicines” (Peru) Pooled procurement – Negotiating power of volume for price, quality, availability, geographic distribution (Jordan: Joint Procurement Department) – Centralised procurement with public tender and accountability for timely, decentralised distribution (Peru) – Procurement from pre-qualified suppliers (Zambia) Financing – Separate drug budgets in facilities (Ghana: NHIA reimbursement) – Basic outpatient drug package for chronic conditions & forecasting budget needs using claims data (Kyrgyzstan) Information generation & disclosure – Civil society & media engagement on stock-outs => Drug Monitoring Unit (Uganda) – Availability discussion in review of national medicines policy (Zambia) 01/10/2015

Medicines Transparency Alliance Sample Policy Suggestions Pharmaceutical management – Developing & implementing formulary process related to STG (Jordan) – National formulary system implementation (Philippines) Financing – Differentiate policy interventions targeting poor, near-poor Access to care & free, high quality, appropriate drugs needed for the poor – Incentivise manufacturing, procurement, availability, prescribing, dispensing of appropriate medicines (according to formularies) – Insure flow of funds (Ghana: NHIA reimbursement times) – Implement policies to incentivize appropriate use of generic first-line products with patient cost-sharing for non-poor where appropriate (Kyrgyzstan) Information generation and disclosure – Routine online data bases of price and availability (Peru, Uganda) – Creation of regional MeTA offices (Peru) – Continued consideration of availability (and other MeTA core principles) in Parliament (Zambia) 01/10/2015

Medicines Transparency Alliance Information Generation and Dissemination Publish processes and outcomes of MeTA pilot phase – WHO Essential Medicines Monitor: – WHO Medicines Documentation Centre: – ICIUM2011: Build evaluation and routine monitoring of impacts into policy change – Data – Tools – Indicators – Evaluation design/methods – Analysis – Dissemination Share experiences and results globally 01/10/2015

Medicines Transparency Alliance Thank you Anita Wagner Skype: anita.wagner International MeTA Secretariat: MeTA: 01/10/2015